使用超临界流体制备已开发纳米药物时维拉帕米的溶解度测定

Solubility measurement of verapamil for the preparation of developed nanomedicines using supercritical fluid.

作者信息

Esfandiari Nadia, Saadati Ardestani Nedasadat, Alwi Ratna Surya, Rojas Adrián, Garlapati Chandrasekhar, Sajadian Seyed Ali

机构信息

Department of Chemical Engineering, Marvdasht Branch, Islamic Azad University, Marvdasht, Iran.

Nanotechnology Research Center, Research Institute of Petroleum Industry (RIPI), P.O. Box 14857-336, Tehran, Iran.

出版信息

Sci Rep. 2023 Oct 10;13(1):17089. doi: 10.1038/s41598-023-44280-7.

DOI:10.1038/s41598-023-44280-7

PMID:37816767

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10564778/

Abstract

A static method is employed to determine the solubilities of verapamil in supercritical carbon dioxide (SC-CO) at temperatures between 308 and 338 K and pressures between 12 and 30 MPa. The solubility of verapamil in SC-CO expressed as mole fraction are in the range of 3.6 × 10 to 7.14 × 10. Using four semi-empirical density-based models, the solubility data are correlated: Chrastil, Bartle, Kumar-Johnston (K-J), and Mendez-Santiago and Teja (MST), two equations of state (SRK and PC-SAFT EoS), expanded liquid models (modified Wilson's models), and regular solution model. The obtained results indicated that the regular solution and PC-SAFT models showed the most noteworthy exactness with AARD% of 1.68 and 7.45, respectively. The total heat, vaporization heat, and solvation heat of verapamil are calculated at 39.62, 60.03, and - 20.41 kJ/mol, respectively. Regarding the poor solubility of verapamil in SC-CO, supercritical anti-solvent methods can be an appropriate choice to produce fine particles of this drug.

摘要

采用静态法测定维拉帕米在308至338 K温度和12至30 MPa压力下于超临界二氧化碳（SC-CO₂）中的溶解度。维拉帕米在SC-CO₂中的溶解度以摩尔分数表示，范围为3.6×10⁻⁵至7.14×10⁻⁵。使用四个基于密度的半经验模型对溶解度数据进行关联：Chrastil模型、Bartle模型、Kumar-Johnston（K-J）模型以及Mendez-Santiago和Teja（MST）模型，还有两个状态方程（SRK和PC-SAFT状态方程）、扩展液体模型（修正的Wilson模型）以及正规溶液模型。所得结果表明，正规溶液模型和PC-SAFT模型显示出最显著的准确性，平均绝对相对偏差（AARD%）分别为1.68和7.45。维拉帕米的总热、汽化热和溶剂化热分别计算为39.62、60.03和 -20.41 kJ/mol。鉴于维拉帕米在SC-CO₂中的溶解度较低，超临界抗溶剂法可能是制备该药物细颗粒的合适选择。